Ezequiel Mariano Rivero1, Leandro Marcelo Martinez2, Carlos David Bruque3, Lucia Gargiulo1, Ariana Bruzzone4, Isabel Alicia Lüthy1. 1. Laboratory of Hormones and Cancer, Instituto de Biología y Medicina Experimental (IBYME) - CONICET, Ciudad Autónoma de Buenos Aires, Argentina. 2. Research Institute, Hospital for Special Surgery, New York, NY, USA. 3. ANLIS, Centro Nacional de Genética Médica, Ciudad Autónoma de Buenos Aires, Argentina. 4. Instituto de Investigaciones Bioquímicas Bahía Blanca INIBIBB-CONICET, Bahía Blanca, Argentina.
Abstract
AIMS: Breast cancer is the most frequently diagnosed and leading cause of cancer death among women worldwide. It was classified within molecular intrinsic subtypes: luminal A, luminal B, human epidermal growth factor receptor 2-enriched and basal-like. Epinephrine and norepinephrine, released during stress, bind to adrenoceptors. α2 -adrenoceptors are encoded by the ADRA2A, ADRA2B and ADRA2C genes and β2 by ADRB2. METHODS: We compiled several publicly available Affymetrix gene expression datasets, obtaining a large cohort of 1924 patients with distant metastasis-free survival (DMFS) data and evaluated the association between adrenoceptor expression, clinicopathological markers and outcome. RESULTS: ADRA2A high expressing tumours also expressed hormone receptors and presented diminished tumour size, grade and not compromised lymph nodes. ADRB2 high expression was found in smaller, low grade, oestrogen receptor-positive tumours. Both were significantly associated with the absence of metastasis. High expression of ADRA2C was positively associated with increased tumour size and metastatic relapse. We observed a significant increase in DMFS of patients with high ADRA2A (hazard ratio 0.54, 95% CI 0.45-0.65, P < .001) and ADRB2 (0.77, 0.64-0.93, P = .006) expression and a decrease with ADRA2C high expression (1.45, 1.16-1.81, P = .001). For patients with luminal tumours, ADRA2A was the only factor that retained its significance as an independent predictor of DMFS while ADRA2C expression was an independent predictor for worse prognosis in basal-like tumours. CONCLUSIONS: We herein provide new insight for a potential role of ADRA2A and ADRA2C in breast cancer. In low- and medium-income countries, their incorporation to routine immunohistochemistry analysis of biopsies or tumour samples, could provide additional low-cost prognostic factors.
AIMS: Breast cancer is the most frequently diagnosed and leading cause of cancer death among women worldwide. It was classified within molecular intrinsic subtypes: luminal A, luminal B, humanepidermal growth factor receptor 2-enriched and basal-like. Epinephrine and norepinephrine, released during stress, bind to adrenoceptors. α2 -adrenoceptors are encoded by the ADRA2A, ADRA2B and ADRA2C genes and β2 by ADRB2. METHODS: We compiled several publicly available Affymetrix gene expression datasets, obtaining a large cohort of 1924 patients with distant metastasis-free survival (DMFS) data and evaluated the association between adrenoceptor expression, clinicopathological markers and outcome. RESULTS:ADRA2A high expressing tumours also expressed hormone receptors and presented diminished tumour size, grade and not compromised lymph nodes. ADRB2 high expression was found in smaller, low grade, oestrogen receptor-positive tumours. Both were significantly associated with the absence of metastasis. High expression of ADRA2C was positively associated with increased tumour size and metastatic relapse. We observed a significant increase in DMFS of patients with high ADRA2A (hazard ratio 0.54, 95% CI 0.45-0.65, P < .001) and ADRB2 (0.77, 0.64-0.93, P = .006) expression and a decrease with ADRA2C high expression (1.45, 1.16-1.81, P = .001). For patients with luminal tumours, ADRA2A was the only factor that retained its significance as an independent predictor of DMFS while ADRA2C expression was an independent predictor for worse prognosis in basal-like tumours. CONCLUSIONS: We herein provide new insight for a potential role of ADRA2A and ADRA2C in breast cancer. In low- and medium-income countries, their incorporation to routine immunohistochemistry analysis of biopsies or tumour samples, could provide additional low-cost prognostic factors.
Authors: Thomas Karn; Dirk Metzler; Eugen Ruckhäberle; Lars Hanker; Regine Gätje; Christine Solbach; Andre Ahr; Marcus Schmidt; Uwe Holtrich; Manfred Kaufmann; Achim Rody Journal: Breast Cancer Res Treat Date: 2009-05-20 Impact factor: 4.872
Authors: Deena M A Gendoo; Natchar Ratanasirigulchai; Markus S Schröder; Laia Paré; Joel S Parker; Aleix Prat; Benjamin Haibe-Kains Journal: Bioinformatics Date: 2015-11-24 Impact factor: 6.937
Authors: Makoto R Hara; Jeffrey J Kovacs; Erin J Whalen; Sudarshan Rajagopal; Ryan T Strachan; Wayne Grant; Aaron J Towers; Barbara Williams; Christopher M Lam; Kunhong Xiao; Sudha K Shenoy; Simon G Gregory; Seungkirl Ahn; Derek R Duckett; Robert J Lefkowitz Journal: Nature Date: 2011-08-21 Impact factor: 49.962
Authors: Jordi Barretina; Giordano Caponigro; Nicolas Stransky; Kavitha Venkatesan; Adam A Margolin; Sungjoon Kim; Christopher J Wilson; Joseph Lehár; Gregory V Kryukov; Dmitriy Sonkin; Anupama Reddy; Manway Liu; Lauren Murray; Michael F Berger; John E Monahan; Paula Morais; Jodi Meltzer; Adam Korejwa; Judit Jané-Valbuena; Felipa A Mapa; Joseph Thibault; Eva Bric-Furlong; Pichai Raman; Aaron Shipway; Ingo H Engels; Jill Cheng; Guoying K Yu; Jianjun Yu; Peter Aspesi; Melanie de Silva; Kalpana Jagtap; Michael D Jones; Li Wang; Charles Hatton; Emanuele Palescandolo; Supriya Gupta; Scott Mahan; Carrie Sougnez; Robert C Onofrio; Ted Liefeld; Laura MacConaill; Wendy Winckler; Michael Reich; Nanxin Li; Jill P Mesirov; Stacey B Gabriel; Gad Getz; Kristin Ardlie; Vivien Chan; Vic E Myer; Barbara L Weber; Jeff Porter; Markus Warmuth; Peter Finan; Jennifer L Harris; Matthew Meyerson; Todd R Golub; Michael P Morrissey; William R Sellers; Robert Schlegel; Levi A Garraway Journal: Nature Date: 2012-03-28 Impact factor: 49.962
Authors: Guillermo N Armaiz-Pena; Julie K Allen; Anthony Cruz; Rebecca L Stone; Alpa M Nick; Yvonne G Lin; Liz Y Han; Lingegowda S Mangala; Gabriel J Villares; Pablo Vivas-Mejia; Cristian Rodriguez-Aguayo; Archana S Nagaraja; Kshipra M Gharpure; Zheng Wu; Robert D English; Kizhake V Soman; Mian M K Shahzad; Mian M K Shazhad; Maya Zigler; Michael T Deavers; Alexander Zien; Theodoros G Soldatos; David B Jackson; John E Wiktorowicz; Madeline Torres-Lugo; Tom Young; Koen De Geest; Gary E Gallick; Menashe Bar-Eli; Gabriel Lopez-Berestein; Steve W Cole; Gustavo E Lopez; Susan K Lutgendorf; Anil K Sood Journal: Nat Commun Date: 2013 Impact factor: 14.919
Authors: Stephen Ph Alexander; John A Cidlowski; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2017-12 Impact factor: 8.739
Authors: Rafael Caparica; Yaohua Ma; Claudia De Angelis; François Richard; Christine Desmedt; Ahmad Awada; Martine Piccart; Edith A Perez; Alvaro Moreno-Aspitia; Sunil Badve; E Aubrey Thompson; Evandro de Azambuja Journal: Clin Breast Cancer Date: 2021-12-02 Impact factor: 3.078
Authors: Luisina M Solernó; Natasha T Sobol; María F Gottardo; Carla S Capobianco; Maximiliano R Ferrero; Liliana Vásquez; Daniel F Alonso; Juan Garona Journal: Sci Rep Date: 2022-09-08 Impact factor: 4.996